Caliper and Seegene combine for diagnostic assays pact
This article was originally published in Clinica
Executive Summary
Korean firm Seegene is to make its complete line of multiplex diagnostic assays available on Caliper Life Sciences’ LabChip Dx platform. Under the terms of the deal, the two companies will co-market the LabChip Dx platform as the system of choice for Seegene’s SeePlex assays outside of the US. The firms will also work together to expand the number of diagnostic tests available on the LabChip system. Caliper (Hopkinton, Massachusetts) says LabChip is a high-throughput, multiplex, sample-processing, microfluidic system that includes diagnostic identification, scoring and reporting software. It was developed in collaboration with Seoul-based Seegene. Seegene’s assays use dual priming oligonucleotide technology, which detects many pathogens in a single reaction and can be used on electrophoresis platforms. The assays test for a range of pathogens, and allow screening for respiratory diseases, human papillomavirus, Candida, sepsis, diarrhoea, meningitis, tuberculosis and STDs. Financial terms of the deal were not disclosed.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals